Unlike cutaneous melanoma, treatments involving immune checkpoint and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibition have shown limited efficacy in extending survival for those with metastasized uveal melanoma [7]. The gene discussed is BRAF; the disease is cutaneous melanoma.